In a study conducted by the United States Preventive Services Task Force, testing in nearly 77,000 men ages 55 to 74, found that the commonly used prostate cancer screening P.S.A. blood test did not save lives. The conclusion is a follow-up to a 2009 study and has been published The Journal of the National Cancer Institute. The researchers found the type of cancer typically detected by screening is so slow-growing that it typically doesn't doesn't cause major harm before some other ailment takes the patients life. Also, the risk of dying from prostate cancer didn't change whether it was first detected through a screening or from the patient showing symptoms. Conversely, the study found that the screenings can lead to aggressive treatments that leave men impotent, incontinent or both. Some critics of the study point out that their still is not conclusive evidence that screening doesn't benefit those who are high risk patients. You can read the entire article at the New York Times.